DrugPatentWatch Database Preview

Details for Patent: 10,010,507

« Back to Dashboard

Which drugs does patent 10,010,507 protect, and when does it expire?

Patent 10,010,507 protects IMBRUVICA and is included in one NDA.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 10,010,507

Title:	Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Abstract:	Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Chong; Ching W. (Fremont, CA), Kuehl; Robert (San Francisco, CA), Tan; Heow (Cupertino, CA), Atluri; Harisha (Palo Alto, CA)
Assignee:	Pharmacyclics LLC (Sunnyvale, CA)
Application Number:	15/909,779
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,010,507

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No			Y
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-002	Feb 16, 2018		RX	Yes	No			Y
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	No			Y
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 10,010,507

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	103832
Australia	2016226279
Canada	2976695
China	107427498
European Patent Office	3265084
Israel	253995
Japan	2018507200